Scholarlink

Background <p>Vascular endothelial growth factor receptor-3 (VEGFR-3) is overexpressed in tumor-induced lymphangiogenesis. TMVP1446/GS5 is a peptide analogue specifically targeting VEGFR-3, developed through substitution of the original peptide TMVP1446 with non-natural amino acids and terminal modification. This study aimed to evaluate the potential of <sup>68</sup>Ga-labeled TMVP1446/GS5 as a probe for imaging primary tumors and metastatic lymph nodes.</p> Results <p>[<sup>68</sup>Ga]Ga-DOTA-TMVP1446/GS5 exhibited excellent labeling yield and radiochemical purity (RCP). Radio-HPLC analysis demonstrated comparable radiochemical and chemical stability to the original probe. Although stability in mouse plasma remained limited, [<sup>68</sup>Ga]Ga-DOTA-TMVP1446/GS5 exhibited modestly improved metabolic stability than the original probe. Cellular assays and surface plasmon resonance (SPR) analysis showed comparable or slightly higher binding affinity to VEGFR-3 relative to the original probe. In B16F10 subcutaneous xenografts, [<sup>68</sup>Ga]Ga-DOTA-TMVP1446/GS5 showed stronger and more sustained tumor uptake compared to the original probe, along with extended in vivo retention. At 2&#xa0;h post-injection, tumor uptake reached 4.90 ± 0.36%ID/g, approximately five times of the original probe (1.03 ± 0.06%ID/g). In B16F10 footpad lymph node metastasis model, [<sup>68</sup>Ga]Ga-DOTA-TMVP1446/GS5 enabled clear visualization of metastatic lymph nodes.</p> Conclusions <p>[<sup>68</sup>Ga]Ga-DOTA-TMVP1446/GS5 showed enhanced and sustained tumor uptake and extended in vivo retention. It provided relatively superior imaging of both primary tumors and metastatic lymph nodes at later time points, suggesting its potential for further research.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhanced in-vivo persistence and PET imaging performance of [68Ga]Ga-DOTA-TMVP1446/GS5 as a VEGFR-3 radiotracer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • Jing Wang,
  • Xi Chen,
  • Sixuan Cheng,
  • Jie Li,
  • Yue Sun,
  • Yahan Song,
  • Fangle Cai,
  • Fei Li,
  • Dawei Jiang,
  • Ling Xi

摘要

Background

Vascular endothelial growth factor receptor-3 (VEGFR-3) is overexpressed in tumor-induced lymphangiogenesis. TMVP1446/GS5 is a peptide analogue specifically targeting VEGFR-3, developed through substitution of the original peptide TMVP1446 with non-natural amino acids and terminal modification. This study aimed to evaluate the potential of 68Ga-labeled TMVP1446/GS5 as a probe for imaging primary tumors and metastatic lymph nodes.

Results

[68Ga]Ga-DOTA-TMVP1446/GS5 exhibited excellent labeling yield and radiochemical purity (RCP). Radio-HPLC analysis demonstrated comparable radiochemical and chemical stability to the original probe. Although stability in mouse plasma remained limited, [68Ga]Ga-DOTA-TMVP1446/GS5 exhibited modestly improved metabolic stability than the original probe. Cellular assays and surface plasmon resonance (SPR) analysis showed comparable or slightly higher binding affinity to VEGFR-3 relative to the original probe. In B16F10 subcutaneous xenografts, [68Ga]Ga-DOTA-TMVP1446/GS5 showed stronger and more sustained tumor uptake compared to the original probe, along with extended in vivo retention. At 2 h post-injection, tumor uptake reached 4.90 ± 0.36%ID/g, approximately five times of the original probe (1.03 ± 0.06%ID/g). In B16F10 footpad lymph node metastasis model, [68Ga]Ga-DOTA-TMVP1446/GS5 enabled clear visualization of metastatic lymph nodes.

Conclusions

[68Ga]Ga-DOTA-TMVP1446/GS5 showed enhanced and sustained tumor uptake and extended in vivo retention. It provided relatively superior imaging of both primary tumors and metastatic lymph nodes at later time points, suggesting its potential for further research.

Graphical abstract